Remgro Earnings Call Signals Profits, Discipline, Caution

Remgro ((RMGOF)) has held its Q2 earnings call. Read on for the main highlights of the call.

Remgro’s latest earnings call carried a confident but measured tone. Management highlighted sharply stronger earnings, rising dividends and solid cash generation, underpinned by operational turnarounds at key assets. At the same time, they were candid about sector-specific headwinds, from sugar and beverages to Middle East healthcare exposure.

Headline earnings surge on broad-based portfolio momentum

Headline earnings jumped about 38.8% to ZAR 5.2 billion for the six months to 31 December 2025, with HEPS climbing from ZAR 6.72 to ZAR 9.31. Management stressed that this was not a one-off, but reflected broad-based improvement across healthcare, consumer, industrial and financial investments.

Dividends and cash pile grow sharply at the centre

Sustainable ordinary dividends received at the centre rose roughly 34% to ZAR 2.4 billion, giving Remgro more firepower for capital allocation. The interim dividend was lifted by about 80.2% to ZAR 1.73 per share, while net cash at the centre increased by ZAR 3.7 billion to ZAR 12 billion, taking total liquidity to just under ZAR 19 billion.

Portfolio reshaping and monetisations unlock capital

Remgro completed the CIVH/Vodacom transaction, including its share of a ZAR 2.66 billion pre-implementation dividend from Maziv, marking a major portfolio milestone. The group also sold its remaining British American Tobacco stake, unbundled media assets and further monetised FirstRand, together crystallising several billion rand of value.

Mediclinic underpins performance with robust growth

Mediclinic delivered a strong set of numbers, with revenue up 10% to $2.6 billion and adjusted EBITDA up 23% to $397 million, supported by solid Southern Africa results. Adjusted earnings surged 91% to $159 million, and cash conversion improved to 84% year-to-date, with management targeting 90–100% by year-end.

CIVH and Maziv achieve profitability and free cash flow gains

CIVH shifted from loss to profit in its contribution to Remgro, reflecting improving scale and operating leverage across fibre assets like Vumatel. Free cash flow before capital expenditure rose about 31% to ZAR 1.5 billion, while CIVH’s valuation nudged higher to ZAR 16.2 billion, or nearly 20% uplift when including the pre-implementation dividend.

Consumer brands stage a turnaround at Rainbow and Heineken

Rainbow Foods produced a substantial turnaround, with its contribution rising about 110% to ZAR 535 million on the back of improved execution and pricing. Heineken Beverages grew revenue by around 2%, but more importantly swung to a ZAR 155 million profit from a loss, expanding margins and lifting its valuation by roughly 12%.

Industrial and financial holdings quietly deliver

Industrial and financial investments added steady earnings support, led by OUTsurance, whose contribution rose 14.3% to ZAR 713 million. Air Products grew its contribution by 11.4% to ZAR 380 million, while TotalEnergies more than doubled its contribution thanks largely to a one-off transit pipeline cost refund.

INAV growth lags profits amid disciplined valuations

Intrinsic net asset value per share rose a modest 1.6% to ZAR 297.30, or 3.4% when adjusting for distributions, well below the growth in headline earnings. Management emphasised a conservative valuation framework built on discounted cash flows with moderated terminal growth, even as discount rates moved lower in the period.

Corporate simplification and restructuring gather pace

Remgro is pushing to simplify its structure, striking an in-principle deal to take full ownership of Mediclinic Southern Africa to better align regional interests. The group also highlighted progress on the next stage of the Herotel transaction and signalled that options such as share buybacks are actively under review as capital allocation tools.

RCL Foods hit by sugar-driven earnings decline

RCL Foods’ contribution to Remgro’s headline earnings fell about 31%, with continuing operations’ EBITDA down almost 15%, mainly due to sugar. The sugar division underperformed by roughly ZAR 250 million as industry pressures weighed on pricing and volumes, dragging return on invested capital below 10%.

Sugar sector stress and regulatory uncertainty weigh on outlook

The local sugar market is under heavy pressure from deep-sea imports, with about 160,000 tonnes arriving by year-end and more afterward, suppressing prices. A delayed tariff review and the uncertain status of Tongaat’s operations add social and industry risk, complicating planning for producers like RCL and threatening margins.

Mediclinic Middle East faces conflict-driven volatility

While Mediclinic’s core performance is strong, management flagged notable volatility in the Middle East business, where seasonality was amplified by regional conflict. They warned that volumes, revenue and cash conversion could be affected over the next several months, introducing geopolitical risk to an otherwise improving earnings story.

Additional operational headwinds at RCL and Heineken Beverages

RCL also faced a pet product recall and plant downtime after the reporting period, disrupting supply and likely compressing short-term margins as brands are rebuilt. At Heineken Beverages, management noted aggressive pricing, illicit trade and tight volumes in categories like spirits and value wine, limiting top-line growth despite margin ambitions.

Valuation, interest-rate moves and deal execution risks

Despite lower discount rates during the period, Remgro moderated its terminal growth assumptions, which capped valuation gains across the portfolio. Management cautioned that recent rises in yields could pressure valuations at the next review, while ongoing operational and regulatory challenges at RCL and a complex Spire exit process add execution risk.

Forward guidance focuses on disciplined capital allocation

Remgro guided toward continued capital discipline, adopting roughly 1.5 times dividend cover and targeting about half of central cash flow as a reference payout over time. With net cash at ZAR 12 billion and liquidity near ZAR 19 billion, the group plans to support growth, consider value-unlocking moves such as buybacks and back operational targets like Mediclinic’s savings and Heineken’s margin recovery.

Remgro’s earnings call painted a picture of a portfolio in transition, with strong profit and dividend growth supported by corporate reshaping and operational turnarounds. Risks remain in sugar, beverages and the Middle East, and valuation gains are deliberately restrained, but management’s tone on execution and capital discipline suggests a constructive outlook for patient investors.